What can be expected after 60 days on the same regimen (sublingual estradiol 0.5 mg every 12 hours and oral spironolactone 50 mg daily) in a male with a single testicle?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Expected Outcomes at 60 Days on Sublingual Estradiol 0.5 mg Every 12 Hours + Spironolactone 50 mg Daily

After 60 days on this regimen, a male with a single testicle should expect testosterone suppression to castrate levels (<50 ng/dL) in approximately 70–80% of cases, with stable feminizing changes including early breast development, body fat redistribution, and reduced muscle mass. 1

Testosterone Suppression Timeline

  • Most individuals achieve testosterone levels <50 ng/dL within 2 months when using estradiol therapy, though sublingual administration may require higher cumulative doses than transdermal routes to achieve equivalent suppression 1

  • The twice-daily sublingual dosing (0.5 mg every 12 hours = 1 mg total daily) provides pulsed estradiol exposure with peak levels occurring 1 hour after each dose, followed by rapid decline 2, 3

  • Sublingual estradiol peaks at 144 pg/mL within 1 hour but returns to baseline by 8 hours, necessitating multiple daily doses to maintain therapeutic levels 2

  • Continuous transdermal estradiol suppresses testosterone more effectively than pulsed sublingual dosing at equivalent total daily doses, achieving castrate levels faster and more reliably 1

Spironolactone Contribution at 50 mg Daily

  • Spironolactone 50 mg daily does NOT enhance testosterone suppression beyond what estradiol alone achieves, and may actually impair achievement of target estradiol levels 4

  • The 50 mg dose is below the typical 100–200 mg daily range studied for acne treatment and may provide minimal antiandrogen effect 5

  • Spironolactone use was associated with lower serum estradiol levels (285 pg/dL vs 427 pg/dL on estradiol monotherapy), suggesting interference with estradiol pharmacokinetics 6

Expected Hormone Levels at 60 Days

  • Serum estradiol levels on 1 mg total daily sublingual dosing typically range 100–200 pg/mL when measured as trough levels (before next dose), though peak levels reach 144 pg/mL transiently 2

  • Over 70% of individuals achieve treatment goals (adequate estradiol and testosterone suppression) on 4 mg oral estradiol daily or more, suggesting the current 1 mg sublingual dose may be subtherapeutic for many 4

  • Nearly one-third of patients do not achieve adequate testosterone suppression on 6–8 mg oral estradiol daily, highlighting substantial individual variability 4

  • The estradiol-to-estrone ratio is higher with sublingual administration (1.1 vs 0.7), though the clinical significance remains unclear 2

Physical Feminization at 60 Days

  • Breast development begins within the first 2–3 months of therapy, with tenderness and early budding as initial signs 7

  • Body fat redistribution toward a gynoid pattern (hips, thighs, buttocks) becomes noticeable by 2–3 months 8

  • Decreased muscle mass and strength begin within the first 3 months as testosterone declines 8

  • Skin softening and decreased sebum production occur relatively early, within 1–3 months 8

  • Testicular atrophy in the remaining testicle progresses gradually over months to years 8

Common Pitfalls and Optimization Strategies

Dosing Inadequacy

  • The current 1 mg total daily sublingual dose is likely suboptimal for most individuals, as studies show 4–8 mg oral/sublingual daily is often required for adequate suppression 4

  • Twice-daily sublingual dosing provides no advantage over once-daily for testosterone suppression, contrary to theoretical expectations 1

  • Transdermal estradiol (100–200 mcg/day patches) achieves superior testosterone suppression with lower total estradiol doses and more stable serum levels 1

Spironolactone Concerns

  • Consider discontinuing spironolactone if estradiol levels remain subtherapeutic, as it may impair estradiol absorption or metabolism without providing additional testosterone suppression 4, 6

  • Spironolactone 50 mg daily is below the evidence-based dose range for meaningful antiandrogen effects (typically 100–200 mg daily) 5

  • Potassium monitoring is not required in young, healthy individuals without renal disease, hypertension, or concurrent medications affecting potassium 5

Monitoring Requirements

  • Measure serum testosterone and estradiol levels at 60 days to guide dose titration, as individual variability is substantial 4

  • Target testosterone <50 ng/dL and estradiol 100–200 pg/mL (measured as trough levels before next dose) 1, 4

  • If testosterone remains >50 ng/dL at 60 days, increase sublingual estradiol to 1 mg twice daily (2 mg total) or switch to transdermal patches 0.1–0.2 mg/24 hours 1

Cardiovascular and Thrombotic Safety

  • Sublingual/oral estradiol increases venous thromboembolism risk 2–4-fold compared to transdermal routes, which show no increased VTE risk 7, 9

  • Transdermal estradiol is strongly preferred over oral/sublingual formulations due to superior cardiovascular and thrombotic safety profiles 7, 8

  • Ethinyl estradiol should never be used for gender-affirming therapy due to substantially higher thrombotic risk than bioidentical 17β-estradiol 7, 8

  • Smoking significantly amplifies cardiovascular and thrombotic risks with any estrogen formulation and should be strongly discouraged 9

Single Testicle Considerations

  • Having one testicle versus two does not substantially alter testosterone suppression requirements, as the remaining testicle compensates to maintain near-normal baseline testosterone production 1

  • Testosterone suppression kinetics should be similar to individuals with two testes, though baseline testosterone may be slightly lower 1

  • The remaining testicle will undergo progressive atrophy with sustained estradiol therapy, potentially reducing fertility over time 8

Recommended Next Steps at 60 Days

  1. Obtain fasting morning testosterone and estradiol levels (trough, before next sublingual dose) to assess adequacy of current regimen 4

  2. If testosterone >50 ng/dL, increase sublingual estradiol to 1 mg twice daily (2 mg total) OR switch to transdermal patches 0.1 mg/24 hours twice weekly 1

  3. If estradiol <100 pg/mL, increase sublingual dose or switch to transdermal route for more stable levels 1, 2

  4. Consider discontinuing spironolactone 50 mg if it provides no measurable benefit and may be impairing estradiol levels 4, 6

  5. Reassess at 90–120 days after any dose adjustment to allow steady-state hormone levels 1

References

2
Research

Pharmacokinetics of Sublingual Versus Oral Estradiol in Transgender Women.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2022

3
Research

Sublingual absorption of micronized 17beta-estradiol.

American journal of obstetrics and gynecology, 1981

5
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

7
Guideline

Estradiol Hormone Replacement Therapy Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

8
Guideline

Estradiol Patch Therapy in Men

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

9
Guideline

Hormone Replacement Therapy Initiation and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

In a trans woman taking oral estradiol 3 mg daily and spironolactone up to 200 mg daily for several months with serum testosterone 180–437 ng/dL and loss of nocturnal erections, is permanent penile shortening likely?
In a 19‑year‑old transgender woman taking oral estradiol 3 mg daily and spironolactone up to 200 mg daily, with serum testosterone fluctuating between approximately 180 ng/dL and 437 ng/dL over several months and loss of nocturnal erections, will this regimen cause permanent penile shortening?
I'm a 19‑year‑old assigned male at birth with baseline testosterone ~654 ng/dL, thick facial hair and normal erectile function; after starting estradiol (up to 3 mg daily) and spironolactone (up to 100 mg daily) my testosterone dropped to ~180 ng/dL and I've lost spontaneous morning/nocturnal erections—should I adjust my hormone regimen to preserve spontaneous erections, and what target testosterone level is appropriate?
As a transgender woman taking oral estradiol 3 mg daily and spironolactone up to 200 mg daily, with serum testosterone between 180 and 437 ng/dL for several months and loss of nocturnal erections, why wouldn't this regimen and timeline cause permanent penile shrinkage?
In a 19‑year‑old transgender woman (assigned male at birth) with baseline male‑range total testosterone, thick facial hair, and normal erectile function, who is on estradiol and spironolactone and now has fluctuating testosterone levels with loss of nocturnal erections, how should anti‑androgen therapy be adjusted to achieve consistent testosterone suppression while preserving desired sexual function?
Why is asthma classified as a disease?
In a patient with a known partial‑thickness left gluteus minimus tear and moderate left‑sided and mild right‑sided L2‑L3 neuroforaminal narrowing with Modic type 1/2 changes, if the hip examination is not convincing for a gluteus minimus tear, could the hip pain actually be referred from the lumbar spine or sacroiliac joint?
In a patient with unstable angina or NSTEMI who still has chest pain after three sublingual nitroglycerin doses, how should an intravenous nitroglycerin drip be used, including its indications, contraindications, titration parameters, and when to add morphine?
How should autonomic dysfunction be screened and managed in adult patients with amyotrophic lateral sclerosis, including orthostatic hypotension, excessive sweating, bladder dysfunction, and gastrointestinal dysmotility?
Can clindamycin be given at standard adult doses in patients with acute renal failure, including those on dialysis, and what safety considerations should be monitored?
A 79-year-old patient on amlodipine 5 mg daily has a blood pressure of 150/60 mm Hg and headache; should we add enalapril (Envas) 2.5 mg once daily?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question